Klotho Neurosciences (KLTO) Competitors $0.75 +0.07 (+10.12%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock KLTO vs. KYTX, IOBT, MCRB, CLYM, CTOR, FATE, HURA, CGEN, ACOG, and GNLXShould you be buying Klotho Neurosciences stock or one of its competitors? The main competitors of Klotho Neurosciences include Kyverna Therapeutics (KYTX), IO Biotech (IOBT), Seres Therapeutics (MCRB), Climb Bio (CLYM), Citius Oncology (CTOR), Fate Therapeutics (FATE), TuHURA Biosciences (HURA), Compugen (CGEN), Alpha Cognition (ACOG), and Genelux (GNLX). These companies are all part of the "pharmaceutical products" industry. Klotho Neurosciences vs. Its Competitors Kyverna Therapeutics IO Biotech Seres Therapeutics Climb Bio Citius Oncology Fate Therapeutics TuHURA Biosciences Compugen Alpha Cognition Genelux Klotho Neurosciences (NASDAQ:KLTO) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Is KLTO or KYTX more profitable? Kyverna Therapeutics' return on equity of -64.98% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Klotho NeurosciencesN/A -325.88% -242.15% Kyverna Therapeutics N/A -64.98%-56.17% Which has stronger earnings and valuation, KLTO or KYTX? Klotho Neurosciences has higher earnings, but lower revenue than Kyverna Therapeutics. Klotho Neurosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKlotho NeurosciencesN/AN/A-$6.15M-$0.45-1.66Kyverna Therapeutics$7.03M23.69-$127.48M-$3.68-1.05 Do institutionals & insiders believe in KLTO or KYTX? 20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 26.7% of Klotho Neurosciences shares are held by insiders. Comparatively, 22.0% of Kyverna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, KLTO or KYTX? Klotho Neurosciences has a beta of 10.9, indicating that its stock price is 990% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500. Does the media prefer KLTO or KYTX? In the previous week, Kyverna Therapeutics had 12 more articles in the media than Klotho Neurosciences. MarketBeat recorded 14 mentions for Kyverna Therapeutics and 2 mentions for Klotho Neurosciences. Klotho Neurosciences' average media sentiment score of 0.69 beat Kyverna Therapeutics' score of 0.45 indicating that Klotho Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Klotho Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend KLTO or KYTX? Kyverna Therapeutics has a consensus price target of $15.60, indicating a potential upside of 305.19%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Klotho Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kyverna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryKyverna Therapeutics beats Klotho Neurosciences on 9 of the 15 factors compared between the two stocks. Get Klotho Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLTO vs. The Competition Export to ExcelMetricKlotho NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.96M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-1.6622.9031.3626.05Price / SalesN/A516.56387.8788.42Price / CashN/A179.1038.0259.36Price / Book4.405.939.536.60Net Income-$6.15M$31.83M$3.26B$265.65M7 Day Performance-12.94%1.89%2.14%2.00%1 Month Performance-41.04%1.62%3.22%0.46%1 Year PerformanceN/A9.25%30.18%18.88% Klotho Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLTOKlotho NeurosciencesN/A$0.75+10.1%N/AN/A$45.96MN/A-1.66N/AEarnings ReportGap UpKYTXKyverna Therapeutics2.5604 of 5 stars$3.30-6.8%$15.60+372.7%-52.4%$142.73M$7.03M-0.9096News CoverageAnalyst ForecastAnalyst RevisionGap UpIOBTIO Biotech3.1754 of 5 stars$2.05-1.9%$8.67+322.8%+6.1%$142.30MN/A-1.3030Gap DownHigh Trading VolumeMCRBSeres Therapeutics3.1252 of 5 stars$16.25-8.1%$73.67+353.3%+11.6%$142.27MN/A-3.53330CLYMClimb Bio3.4067 of 5 stars$2.02-4.3%$9.00+345.5%N/A$136.88MN/A-2.899Gap UpHigh Trading VolumeCTORCitius Oncology1.3474 of 5 stars$1.70-2.9%$3.00+76.5%-6.4%$133.23MN/A0.00N/APositive NewsFATEFate Therapeutics4.0176 of 5 stars$1.14-5.0%$3.58+214.3%-70.1%$131.48M$8.47M-0.79550Analyst RevisionHURATuHURA Biosciences1.3104 of 5 stars$3.00-2.9%$12.67+322.2%N/A$131.04MN/A0.00N/ACGENCompugen2.1022 of 5 stars$1.46-5.8%$4.00+174.0%-28.9%$130.29M$27.86M-6.6470Positive NewsACOGAlpha Cognition2.1274 of 5 stars$8.09-4.1%$20.00+147.2%N/A$129.60MN/A-5.06N/AInsider TradeGNLXGenelux1.6587 of 5 stars$3.43-3.1%$17.75+417.5%+67.3%$129.55M$10K-3.9910News Coverage Related Companies and Tools Related Companies Kyverna Therapeutics Competitors IO Biotech Competitors Seres Therapeutics Competitors Climb Bio Competitors Citius Oncology Competitors Fate Therapeutics Competitors TuHURA Biosciences Competitors Compugen Competitors Alpha Cognition Competitors Genelux Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLTO) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Klotho Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Klotho Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access